Last reviewed 2026-04-23 · How we verify

U0267 Foam

U0267 Foam is a topical corticosteroid formulation designed to reduce inflammation and provide therapeutic benefit when applied directly to affected skin areas.

U0267 Foam is a topical corticosteroid formulation designed to reduce inflammation and provide therapeutic benefit when applied directly to affected skin areas. Used for Inflammatory skin conditions (specific indication under investigation in Phase 3).

At a glance

Mechanism of action

As a foam formulation, U0267 delivers corticosteroid active ingredient in a lightweight, spreadable vehicle that enhances skin penetration and patient compliance. The corticosteroid component works by suppressing inflammatory cytokines and immune cell activity at the site of application, reducing erythema, pruritus, and other inflammatory skin manifestations.

Approved indications

• Inflammatory skin conditions (specific indication under investigation in Phase 3)

Common side effects

• Local skin irritation
• Burning or stinging at application site
• Skin atrophy (with prolonged use)

Key clinical trials

• Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis One of Two Phase 3 Studies (PHASE3)
• Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis Two of Two Phase 3 Studies (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• U0267 Foam CI brief — competitive landscape report
• U0267 Foam updates RSS · CI watch RSS
• Stiefel, a GSK Company portfolio CI